Abstract
Molecular probes have become an important tool to decipher cell and molecular events, as well as contributing to clinical diagnosis. In this study, we report on a novel bioluminescence affiprobe and evaluate its functionality by monitoring HER2 expression in the prostate cancer cells. The proposed bioluminescence affiprobe consists of a binding domain, an HER2 specific affibody molecule and a bioluminescent domain, recombinant Renilla luciferase. The experiments indicate that bioluminescence affiprobe can serve as a reliable and user-friendly probe for the detection of human HER2 positive prostate cells as well as ex vivo based detection of HER2-positive human prostate cancer specimens using luminometeric-based assays.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
